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ABSTRACT 
 
Objective: Down’s syndrome (DS) is associated with an increased risk of diabetes, 
particularly in young children. HLA-mediated risk is however decreased in children 
with DS and diabetes (DSD). We hypothesised that early-onset diabetes in children 
with DS is aetiologically different from autoimmune diabetes.  
Research design and methods: Clinical and immunogenetic markers of autoimmune 
diabetes were studied in 136 individuals with DSD and compared with 194 age and 
sex-matched individuals with type 1 diabetes, 222 with DS and 671 healthy controls. 
HLA class II was analysed by PCR-SSP. Islet autoantibodies were measured by 
radioimmunoassay.   
Results:  Age-at-onset of diabetes was biphasic with 22% of DS children diagnosed 
before age 2 years, compared with only 4% in this age group in type 1 diabetes in the 
general population (p<0.0001). The frequency of the highest risk type 1 diabetes-
associated HLA genotype DR3-DQ2/DR4-DQ8 was decreased in both early and later 
onset DSD compared with age-matched children with type 1 diabetes (p<0.0001) 
although HLA DR3-DQ2 genotypes were increased (p=0.004). Antibodies to GADA 
were observed in all 5 samples tested from children diagnosed ≤ 2 years and persistent 
islet autoantibodies were detected in 72% of DSD cases.  Thyroid and celiac disease 
were diagnosed in 74% and 14% respectively of the DSD cohort.   
Conclusion: Early-onset diabetes in children with DS is unlikely to be aetiologically 
different from autoimmune diabetes occurring in older DS children. Overall these 
studies demonstrate more extreme autoimmunity in DSD typified by early onset 
diabetes with multiple autoimmunity, persistent islet autoantibodies and decreased 
HLA mediated susceptibility.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 3 
 
Children with Down’s syndrome (DS) are at increased risk of thyroid (1), gut (2) and 
islet autoimmunity (3, 4). In the only population-based study which has addressed the 
prevalence of Down's syndrome in type 1 diabetes patients, a more than fourfold 
increased prevalence was observed (5). It has been suggested that diabetes in children 
with DS presents particularly early in life; one study from the 1960s showed a peak 
onset of 8 years of age, compared with 14 years in cases of childhood diabetes (6). In 
a previous study of DS and diabetes, 22% of participants had developed diabetes by 
the age of 2 years, compared with only 7% of those with type 1 diabetes from the 
general population (7). A recent study of 159 DS children diagnosed with type 1 
diabetes (DSD) demonstrated two peaks in diabetes incidence, one occurring before 
the age of 2 years and the other in early adolescence. The mean age at onset in the 
41,983 controls with type 1 diabetes was 8.42 years. (8). These data suggest that 
diabetes occurring before the age of 2 years in DS children may be aetiologically 
different from type 1 diabetes. In the seminal study of type 1 diabetes pathology by 
Foulis et al. (9), three cases of DS and diabetes were described.  A 14 year old boy 
with longstanding diabetes and a 12 year old with recent-onset diabetes both showed 
evidence of lymphocytic infiltration with an absence of insulin staining in the 14 year 
old boy, typical of type 1 diabetes.  The third DS child however, diagnosed with 
diabetes at 18 months whose pancreas was analysed within 2 weeks of diagnosis of 
diabetes, displayed normal insulin staining with no morphological abnormality.  
 
An age-related association between the HLA class II susceptibility haplotypes, 
DRB1*04-DQB1*0302 (DR4-DQ8) and DRB1*03-DQB1*0201(DR3-DQ2) and 
type 1 diabetes in the general population is well established, with an increased 
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frequency in young children with type 1 diabetes (10, 11). These haplotypes also 
appear to contribute to susceptibility to diabetes in DS, but to a lesser degree (12).   
 
The aim of this study therefore was to test the hypothesis that diabetes diagnosed 
before the age of 2 years does not have an autoimmune basis in a well characterised 
cohort of individuals with DSD. Distinguishing whether insulin deficiency in these 
young children is caused by accelerated autoimmunity or an alternative mechanism 
such as beta cell secretary deficit could have consequences for treatment or provide 
insights into a more aggressive autoimmune process in children with DS. 
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Research design and methods 
Study populations 
Down syndrome and diabetes  
An international collection of clinical details, genetic and serum samples from 
children with DSD (Diaploidy) was established in 2010. In the UK, a call for potential 
participants in a study of diabetes in children with DS was sent out by the Diabetes 
Research Network and Diabetes UK. Internationally, a call was sent out through the 
International Society for Pediatric and Adolescent diabetes (ISPAD). All cases 
referred were accepted. By June 2012, 136 individuals with DS and a clinical 
diagnosis of type 1 diabetes had been registered (80 from the UK, 30 from Austria 
and Germany, 7 from other European countries and Australia, and 19 from Kuwait. 
Clinical data on age at diagnosis of diabetes, thyroid disease and celiac disease, 
family history of autoimmunity, treatment history and current height and weight were 
collected by questionnaire.   
 
Control groups:  Three control groups were studied as follows: 
(a) Down’s syndrome controls 
Blood samples were taken from 30 non-diabetic school-aged children with DS (15 
male, 15 female, age range 4 - 21 years) during routine thyroid screening in the area 
covered by the Gloucestershire Health Authority, UK. Aliquots of DNA samples from 
83 children with DS had been collected as controls for a study of congenital heart 
disease in DS (13). 109 DNA samples were also available for analysis from a 
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population-based study of children with DS in Manchester, UK (14). There was no 
clinical evidence of diabetes in any of these children. 
 
(b) Type 1 diabetes controls  
For the HLA analysis, two age at onset and sex-matched children with type 1 diabetes 
for each child with DS and diabetes were randomly selected from the population-
based Bart’s Oxford (BOX) study of type 1 diabetes ongoing since 1985 with 95% 
ascertainment (15).  Age-at-onset data from 1,822 probands diagnosed under the age 
of 21 years from this cohort were used to compare with age-at-onset of the DSD 
cohort.  
 
(c) Healthy control subjects 
HLA genotypes from 621 adult white UK controls with no history of autoimmune 
disease were kindly sent to us by Professor Steven Gough at the Institute of 
Biomedical Research, University of Birmingham, UK and have been described 
previously (16).  
 
Ethical permission 
Ethical permission had been granted for all studies described and written informed 
consent was obtained from the participant, parent or guardian, as appropriate, for all 
samples collected (MREC/02/6/26).  
 
Genetic Analysis 
DNA samples were genotyped for all HLA class II HLA DRB1 and DQB1 haplotypes 
by polymerase chain reaction using a DYNAL reli SSO system (Invitrogen DYNAL 
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UK). DRB1*04 alleles were subtyped using the polymerase chain reaction with 
sequence specific primers. Haplotypes were derived from established patterns of 
linkage diqequilibrium. The established type 1 diabetes-associated haplotype HLA 
DRB1*0401-DQB1*0302 was abbreviated to DR4-DQ8 and HLA DRB1*03-
DQB1*0201 abbreviated to DR3-DQ2. Non-risk haplotypes were described as X.  
Analysis of HLA data was restricted to individuals with DSD diagnosed under the age 
of 21 years to avoid the issue that some older individuals with DSD may have type 2 
diabetes and to allow age-matching with individuals participating in the Bart’s Oxford 
study of type 1 diabetes (11).  
 
Islet autoantibody analysis 
Antibodies to GAD65 (GADA) ,IA-2ic (IA-2A) and ZnT8RA/WA were measured by 
radioimmunoassay as previously described (15, 17). The laboratory defined assay 
sensitivities and specificities of GADA were 86% and 99%, and of IA-2A 72% and 
93% respectively, in the Third Diabetes Antibody Standardization Program (18). The 
inter-assay coefficient of variation was 9% at 14 WHO units/ml (GADA), 14% at10 
WHO units/ml (IA-2A), 16% for ZnT8RA and 27% for ZnT8WA, both at 1.8 units.  
Serum samples were available on 43 individuals with DSD.  Due to the nature of the 
Diaploidy cross-sectional study design, serum samples collected at diagnosis were not 
available for analysis. Time from diagnosis ranged from 1-396 months (median 89 
months), samples collected within 10 years of diagnosis were available from 23 
individuals and, a further 20 samples were collected between 10 and 39 years from 
diagnosis.  Positivity for islet autoantibodies would be supportive of an autoimmune 
aetiology, while a negative post diagnosis result could not be interpreted.   
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Data analysis 
Differences in age-at-onset and frequencies of HLA class II genotypes in children 
with DS and diabetes compared to age-matched children with type 1 diabetes were 
analysed using the chi-squared test.  
 
Results  
Down’s syndrome and diabetes: subject characteristics 
Of 136 individuals with DSD, 69 (51%) were male. Data on clinical diagnosis of 
other autoimmune diseases were available on 92. Of these 68 (74%), had co-existing 
thyroid disease and 11 (14%) had co-existing celiac disease. Seven of 92 (8%) had co-
existing diagnoses of diabetes, thyroid and celiac disease. 
 
Age-at-onset analysis in the DS and diabetes population  
Of 118 patients with DSD diagnosed with diabetes under the age of 21 years, 22% 
were diagnosed with diabetes under the age of 2 years compared with 5% of 1822  
individuals with type 1 diabetes from the general population notified to the BOX 
study  in the same age group (p<0.0001). As shown in Fig 1, there was a biphasic 
pattern in age at diagnosis, with a peak at 1 year of age and another centred around 10 
years of age.  
 
HLA class II analysis  
In the healthy control cohort, only 3% had the highest risk diplotype (DR4-DQ8/DR3-
DQ2), 13% had DR4-DQ8/X, 27% had DR3-DQ2/X and 57% had no risk haplotypes. 
HLA class II frequencies in the DS control population were very similar to the healthy 
control population as shown in figure 2a. As expected the risk haplotypes were 
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increased in 194 individual with type 1 diabetes age and sex-matched with the DSD 
population: 38% had DR4-DQ8/DR3-DQ2, 40% had DR4-DQ8/X, 17% had DR3-
DQ2/X and 5% had no risk haplotypes. Genetic samples were available on 97 
individuals with DSD diagnosed before the age of 21 years. HLA frequencies in the 
DSD cohort were intermediate between the type 1 diabetes and control cohorts. 
Specifically, 17 (17%) had the highest risk diplotype (DR4-DQ8/DR3-DQ2); 23 
(24%) and 31 (32%) had the moderate risk DR4-DQ8 and DR3/DQ2 haplotypes 
respectively and 26 (27%) had no risk haplotypes. In contrast, 5% of 194 age and sex-
matched children with type 1 diabetes from the BOX study (p<0.0001) and 64% of 
222 DS individuals had no risk haplotypes (Figure 2a).   The frequency of the HLA-
DR3-DQ2/X diplotype (where X is not DR4-DQ8 or DR3-DQ2) in DSD (32%) 
however, was increased relative to age-matched patients from the BOX study (17%, 
p=0.004). 
 
There was no difference in HLA-mediated risk in DS children who had developed 
diabetes before and after the age of 2 years (Figure 2b) indicating that diabetes in the 
early-onset cases is unlikely to be aetiologically distinct from the diabetes found in 
older DS children.  
 
Islet autoantibodies  
Despite the extended diabetes duration at the time many samples were collected, islet 
autoantibodies were detected in 72% of the DSD patients for whom serum was 
available (Table 1). Further, all 5 samples from DSD children diagnosed before the 
age of 2 years, were positive for GADA.  
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Conclusions 
 
In this study, we hypothesised that some early-onset cases of diabetes in DS children 
are not autoimmune.  A biphasic distribution in age-at-onset of diabetes in children 
with DS previously observed in a European study of 159 children with DS and 
diabetes compared with 42,000 age-matched individuals with type 1 diabetes (8) was 
confirmed in our study. We also demonstrated, in the largest analysis to date, that 
T1D associated HLA genotypes are decreased in children with DSD. To account for 
this difference in HLA frequencies, we hypothesised that diabetes in some children 
diagnosed under the age of 2 years may be aetiologically different from  autoimmune 
type 1 diabetes.  Analysis of HLA data by age-at-onset however, did not support this 
hypothesis. This shows that DS children with early-onset diabetes are unlikely to have 
an aetiologically distinct form of diabetes. Two children diagnosed within the first 
month of life may have an alternative aetiological basis for their diabetes; the 
remainder were diagnosed at, or after, the age of 6 months, consistent with type 1 
diabetes (19). Autoimmunity was supported by data obtained from post-diagnosis 
analysis of islet autoantibodies: antibodies to GAD were detected in all 5 serum 
samples tested from children diagnosed with diabetes under the age of 2 years. While 
we cannot rule out the possibility that some individuals with DS and early onset 
diabetes have an aetiologically distinct form of diabetes, we suggest that this is rare 
and may present in the first 6 months of life.   
 
 
Our previous study of diabetes in 40 DS children (12) suggested that the frequency of 
autoimmune diabetes-associated HLA class II genotypes was increased in DSD but to 
a lesser extent than might be expected. We confirmed, within a substantially enlarged 
   
 11 
sample, that the frequency of autoimmune-related HLA genotypes were decreased 
with a concomitant increase in non-autoimmune related genotypes in children with 
DSD compared with age matched children with type 1 diabetes. In young European 
populations with type 1 diabetes, 5-10% of individuals do not carry DR4-DQ8 and/or 
DR3-DQ2 (10, 11) but this proportion was increased to 27% in our similarly aged 
cohort of patients with DSD.  This difference was not explained by the inclusion of 
19 children with DS and diabetes from Kuwait, a population where HLA mediated 
susceptibility to diabetes may be different, as the pattern was the same when these 
individuals were removed from the analysis. This increased penetrance of low risk 
HLA class II haplotypes in DSD children mirrors the trend observed in the general 
population as type 1 diabetes incidence is increasing (20-23).  Understanding how 
autoimmunity occurs in the absence of HLA risk genotypes  in children with DS 
could therefore provide important insights into disease mechanisms in the general 
population.  
 
There are limitations to this work. Although it is the largest existing cohort of 
individuals with DS and diabetes on whom serum and DNA is available, the 
Diaploidy study is relatively small. This is however a difficult group to recruit as co-
occurrence of both conditions is rare. The cohort is not population based and 
definitive studies of incidence are not therefore possible. Analysis of islet 
autoantibodies years after diagnosis is not ideal, as antibody levels tend to fall post 
diagnosis, although antibodies to GAD are known to be the most persistent (24) .  
Indeed, in this study at least one islet autoantibody was detectable in 75% of post-
diagnosis samples, with multiple islet autoantibody positivity detectable in serum 
from 8 individuals more than 10 years after diagnosis.   
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There is a wide variation in reported prevalence rates of thyroid disorders in the 
Down’s syndrome population. The prevalence of autoimmune thyroid disease has 
been reported to be at least four-fold higher in children with DS than in the general 
population   (25-27) but a recent longitudinal study suggests that  that this may be an 
overestimation (28).  Celiac disease may be 10 times more common in DS 
populations (2, 29).  Our study suggests that individuals with DS are at risk of 
extreme autoimmunity: co-occurrence of  clinically diagnosed thyroid disease and 
diabetes was observed in 74% while clinically diagnosed celiac disease and diabetes 
was observed in 14% of individuals with DSD.  This was based on data collected by 
questionnaire. The precise aetiology of thyroid disease is therefore unclear and data 
on anti-thyroid antibodies at diagnosis are unavailable.  
 
Overall, a clinical picture of DSD is emerging with earlier onset diabetes, co-
existence of other organ specific autoimmune diseases with persistent islet 
autoantibodies and decreased HLA mediated susceptibility – why might this be?  
Over-expression of type 1 diabetes associated genes on chromosome 21 combined 
with generalised immunological dysfunction in DS appears probable. GWAS 
identified (30) and replicated (31) a chromosome 21q22.3 type 1 diabetes associated 
locus  . The candidate gene is the Ubiquitin associated and SH3 domain containing A 
(UBASH3A) which is expressed in spleen and peripheral blood lymphocytes (32) and 
regulates T cell signalling (33, 34). Over-expression of UBASH3A may therefore 
provide one candidate for the increased frequency of autoimmune disease in Down’s 
syndrome.   Immune cell dysfunction in DS is well established. A smaller thymus in 
DS children has been reported several times (35, 36) and total lymphocyte numbers, 
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including CD4 and CD8 T cell subsets are decreased, particularly in the first two 
years of life. Recent analysis of protein and gene expression in surgically removed 
thymuses from 14 DS patients compared with 42 age-matched controls showed 
reduced expression of AIRE, a chromosome 21 gene product that regulates ectopic 
expression of tissue specific antigens in thymic medullary epithelial cells, a crucial 
mechanism for thymic T cell selection (37). This mechanism could contribute to the 
increased risk of multiple autoimmunity and the earlier onset of diabetes that we have 
observed.   
 
In conclusion, diabetes in DS children is associated with a lower frequency of high 
risk HLA class II susceptibility genes than children matched for age-at-onset of 
diabetes with type 1 diabetes from the general population but this is not caused by a 
subset of children with an aetiologically different early onset form of diabetes. HLA 
DR3-DQ2/X combinations are increased in DSD children, but this does not fully 
explain their very high rates of endocrine autoimmunity. Our data show high rates of 
co-existing organ specific autoimmunity with a high prevalence of residual islet 
autoimmunity and lower frequencies of class II HLA diabetes susceptibility 
haplotypes in DSD. Understanding how this occurs may provide insights into the 
mechanisms underlying type 1 diabetes in the general population.  
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Time 
from 
Diagnosis 
3 islet Ab 2 islet Ab GADA 
alone 
IA-2A 
alone 
ZNT8R/W 
alone 
Negative 
<10 yrs 2 (11%) 4 (21%) 7 (37%) 0 0 6 (31%) 
>1 0 yrs 2 (8%) 6 (25%) 9 (38%) 1 (4%) 0 6 (25%) 
 
Table 1: Residual islet autoantibody positivity in 43 individuals with DSD from 
whom serum was available. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure legends 
 
 
Figure 1: (a) Age at diagnosis of diabetes in individuals with Down’s syndrome 
diagnosed with diabetes compared with (b) individuals with type 1 diabetes from the 
BOX study.  
 
Figure 2: (a) The frequency (%) of type 1 diabetes associated haplotypes in children 
with Down’s syndrome and diabetes (DSD) relative to age-matched children with 
type 1 diabetes (T1D), DS alone and healthy control subjects (HC).  
                (b) The HLA characteristics of diabetes in children with Down’s syndrome 
by age at onset compared with type 1 diabetes. 
 
 


